In March 2022, the World Health Organization issued an interim statement, which set out higher expectations and requirements for the development of a new crown vaccine – that is, ideally, a new crown vaccine should not only prevent serious illness and death, but also prevent infection and transmission. Causes mucosal immunity. As expected by the World Health Organization, CanSino Bio’s inhaled new crown vaccine can prevent the virus from replicating in the upper respiratory tract and block human-to-human transmission. At the same time, the vaccine has the characteristics of long-term stable storage and transportation at 2-8 degrees Celsius, which can greatly reduce the management cost of the vaccination site, reduce the burden of medical resources or underdeveloped areas, and provide convenience for residents in remote areas, especially suitable for Borders, ports, and people working in high-risk jobs.
At present, CanSino Biologics has completed the Phase I and Phase II clinical trials related to vaccine priming and sequential immunization. In terms of safety, the R&D team has also accumulated clinical data of tens of thousands of cases and is conducting Phase III clinical studies.
The management team of CanSino Biology stated that the next step will be to actively promote the emergency use or conditional listing of the inhaled new crown vaccine at home and abroad, so as to establish triple protection against the new coronavirus for the public as soon as possible. CanSino Biologics’ inhaled COVID-19 vaccine is expected to become the world’s first choice for reducing vaccination costs, improving efficiency, and quickly establishing an immune barrier, helping the world fight against the COVID-19 epidemic.
Post time: May-27-2022